Results

1–10 of 19 results for growth

Prophylactic Intraocular Pressure–Lowering Measures in Antivascular Endothelial Growth Factor Therapy: Systematic Review and Meta-Analysis
Parnian Arjmand, MD, MSc, FRCSC, DABO
Annual Meeting Talks
2022
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Endophthalmitis After Intravitreal Injections with 0.05% Aqueous Chlorhexidine vs 5% Povidone-Iodine as Ocular Antiseptics
Murtaza K Adam, MD
Annual Meeting Talks
2022
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Relationship Between Number of Intermediate-Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials
Eleonora Lad, MD, PhD
Annual Meeting Talks
2022
Conversion Rates from Nonexudative to Exudative Age-Related Macular Degeneration: An AAO IRIS® Registry Analysis
Dan A Gong, MD
Annual Meeting Talks
2022
Computerized Analysis of Retinal Vascular Growth Following Intravitreal Bevacizumab Monotherapy in Retinopathy of Prematurity Until Three Years of Age
Swati Agarwal-Sinha, MD, FASRS
Annual Meeting Talks
2021
Clinical Trial Versus Real-World Outcomes With Anti-VEGF Therapy for Branch and Central Retinal Vein Occlusion
Carl J Danzig, MD
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2021